Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

ANAVEX. NY TRÅD ÅRSRAPPORT 2021!!!!


98835 Tasso1 24/11 2021 13:03
Oversigt




24/11 2021 13:13 Solsen 798836



Anavex Så blev igangsætning af forsøg udskudt. Ærgerligt det går så langsomt.

ALS indikationen er til højrebenet og super interessant. Men de skal sq starte de forsøg for at få data.

Håber de melder ud at de får flere hænder til at hjælpe med den håbløse hastighed.

Jeg er stadig positiv på casen :-)



24/11 2021 13:33 Tasso1 598838



Anavex. Lover stadig vigtige resultater i år for RETT og 3-71 i FTD.

Opstart Fragil X, Parkinson image og ubenævnt indikation skubbet til 1. halv. 2021.
Resten som forventet - indtil videre!

Meget spændende med ny stor potentiel indikation ALS - præsentation 29./30. nov.

Vigtigst af alt er at vi stadig forventer resultaterne fra RETT fase 2/3 +17 år inden for den næste ca. 1 måned - tror dette er nøglen til det videre forløb i bl.a. Fragile X m.m.
Har det fint med og giver god mening, at vi afventer RETT før de andre indikationer startes op.

Vi må se om vi får lidt mere kød på i aften kl. 22.30.

https://wsw.com/webcast/cc/avxl20/1492110.




24/11 2021 15:24 Solsen 598844



Ja vi må høre hvad der bliver sagt.

Men jeg kan ikke se hvorfor vi skal afvente forsøgsdata fra 31 pts i Rett for at komme i gang med en endnu større og anden indikation. Hvis de skal analysere de 31 pts til bunds og herefter lave protokollen så skal vi ind i H222 eller senere med det tempo de fører. FragileX folkene sagde jo senest, at forsøget jo helst skulle være startet i går.

Per review artiklerne er også glemte.

Håber Missling åbner lidt for hvad de går og bruger tiden på og hvad de ser i de data de analyserer og analyserer.

Stadig positiv på casen ;-)



24/11 2021 23:20 Solsen 1098858



Anavex Missling imponerer stadig selv om jeg er træt af at vente.

PDD og PD pivotal er også på vej - taler med fda om disse forsøg. Så nye forsøg i 2022 står i kø.

Der blev også spurgt ind til Avatar og de relativt få pts. Men forsøget er med flere pts end tilsvarende US forsøg og med højere dosis så forventningen var mindst lige så gode data.

Ved stærke Avatar data vil man søges markedstilladelse. Ellers afventer man Excellence.

Excellence udvidet i antal for at sikre analyse af de yngre pts i to aldersgrupperinger.

OLE i AD udvidet til 3 år fra 2 år efter ønske fra deltagerne i forsøget (fase 2/3). Placebogruppen er konverteret til behandling for over 90% vedkommende. Der må været helt klar synlig effekt (min kommentar)

Vil partner med Big Pharma i PD og AD så sent som muligt for at få mest værdi til Anavex.

Nogen overlapning mellem rett og fragileX - hvilket nok er årsag til at afvente opstart i FragileX. Vel ok trods alt (min kommentar).

Meget overbevisende i mine øre.




24/11 2021 23:51 Tasso1 1098861



Anavex Udmærket Webcast!

Ingen negative overraskelser og gode kritiske spørgsmål fra de forskellige analytikere!

Helt tydeligt, at RETT Avatar kan blive det store vendepunkt - man vil lade resultaterne tale for sig selv og ud fra disse evt. ansøge FDA om markeds adgang, såfremt resultaterne er overbevisende.
Missling understregede, at man forventede endnu bedre data end i RETT US forsøget pga. af den højere dosis 2-73.
Han understregede også, at RETT US og Avatar ville kunne udgøre en stærk samlet pakke, som tilsammen potentielt ville opfylde kriterierne for det FDA kræver for godkendelse af en sjælden indikation - idet indikationen har en så lille patientgruppe og samtidig ikke har nogen behandlingsmulighed.

Missling gjorde det rimmeligt klart, at Anavex agter at køre/markedsføre de sjældne indikationer, som RETT, Fragile mm. alene - og dermed øge værdien af selskabet.
Han åbnede dog også samtidig lige så klart op for, at Anavex vil søge en større og nødvendig partner, for at få den nødvendige gennemslagskraft, når både Alzheimer og Parkinson skal på markedet - men først når man kan få det optimale økonomiske ud af det, til fordel for Anavex og dets aktionærer! - (det vil blive rigtig dyrt for disse BP`er til den tid - og den eller disse potentielle partneraftaler, vil komme til at hænge som en konstant trussel over shorterne!)

Vedr. Parkinson sagde Missling, at man afventer den fulde datapakke fra fase 2 forsøget, men at man er i tæt dialog med The Fundation ( må være MJFF ), for at finde den bedste struktur, når man skal diskutere protokollen for de 2 fase 3 forsøg i PD og PDD.
Man vil dog ikke afvente Image forsøget!

Tingene trækker ud, men Missling gentog flere gange på spørgsmål fra analytikerne, at man forventede resultaterne fra både Avatar og 3-71 i FTD omkring slutningen af året.

Anavex har ca. 152 mill. $ på bogen og der var ingen snak om yderligere nødvendig kapital - ingen gæld.

Nu er den lovpligtige årsrapport overstået og af vejen.
Næste punkt bliver så fremvisning af videnskabelige dokumentation for, at 2-73 også kan have en effekt i ALS. ( 29.-30. nov. )
Ellers kan vi kun vente på div. nyheder, som altid!

Alt er godt, men en langsomlig proces - casen fuldstædig intakt og positiv!

Shorterne har også reduceret en del fra 5,1 mill. til 4,4 mill. aktier.










25/11 2021 07:10 Tasso1 798867



Anavex. Udskrift Webcast

https://seekingalpha.com/amp/article/4471873-anavex-life-sciences-corp-avxl-ceo-christopher-missling-on-q4-2021-results-earnings-call


Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q4 2021 Results - Earnings Call Transcript
Nov. 24, 2021 9:35 PMAnavex Life Sciences Corp. (AVXL)
Summary

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2021 Earnings Conference Call November 24, 2021 4:30 PM ET

Company Participants

Clint Tomlinson - IR

Christopher Missling - President & CEO

Sandra Boenisch - Principal Financial Officer & Treasurer

Conference Call Participants

Raghuram Selvaraju - H.C. Wainwright

Soumit Roy - Jones Trading

Operator

Welcome to the Anavex Life Sciences Fiscal 2021 Fourth Quarter Conference Call. My name is Vage [ph] and I'll your operator for today's call.

At this time, all participants are in a listen-only mode. [Operator instructions] Please note this conference call is being recorded.

I'll now turn the call over to your host Clint Tomlinson. Sir, you may begin.

Clint Tomlinson

Thank you and good afternoon, everyone. We appreciate you joining us today for Anavex Life Sciences fourth quarter conference call to review financial results and discuss the company's business updates. The tape replay of this call will be available after the call. The call will also be available for replay on Anavex's website at www.anavex.com.

With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.

Following management's remarks, there will be a question and answer session. Before we begin, please note that during this conference call the company will make some projections and forward looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC. This includes without limitation the company's Form-10K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need an ability to obtain future capital and maintenance of intellectual property rights.

And with that, I'd like to turn the call over to Dr. Missling.

Christopher Missling

Thank you, Clint. We really appreciate everyone joining us on today's conference call to review our most recent reported financial results and to provide obvious business update.

We concluded an exceptional fiscal year 2021 while continuing our momentum highlighted by the efficient execution [indiscernible] Phase 2/3 AVATAR clinical trials Rett Syndrome, the ANAVEX 2-73 clinical Phase 2/3 AVATAR Rett Syndrome as well as [indiscernible] ANAVEX 3-71. Starting with our lead drug candidate 2-73, we expect top line results from the second placebo controlled study for the treatment of outpatients with Rett Syndrome, which are expected to be announced [ph] around calendar year end 2021.

This study took place in Australia and the United Kingdom using a higher dose than the US based phase two study and enrolled 33 patients over seven week treatment period, including ANAVEX 2-73 specific precision medicine biomarkers. Top line results from the placebo controlled excellence phase two slash three study for the treatment of patriotic patients with Rett syndrome are expected in the first half of 2022.

This Phase 2/3 study in patriotic patients with Rett Syndrome, with five to 18 will evaluate the safety and efficacy of 2-73 in approximately 84 patients over a 12 week treatment period, including 2-73 specific precision medicine biomarkers. Regarding our Alzheimer disease program top line results from the placebo controlled phase 2b/3 Alzheimer [ph] study for the treatment of Alzheimer disease are confirmed and are expected in the second half of 2022.

The double blind placebo controlled 509 patient late stage Phase 2b/3 study in patients with Alzheimer disease exceeded enrollment of the targeted the number of 52 south across North America, Europe and Australia using others [ph] and ADCS ABL for activities of daily living and function is primary endpoints. This multicenter, double blind clinical trial is measuring efficacy, tolerability and safety of two different ones daily all on ANAVEX 2-73 doses or placebo.

[indiscernible] last month, the independent data safety monitoring board for the company's face 2B free study completed its most recent pre pretend review of the preliminary Phase 2B/3 study data in asthma patients. As specified in a protocol, the [indiscernible] reviewed the interim safety data for the 2-73 Phase 2B/3 disease clinical study and its open label extension attention study. Upon review of the interim safety data, the BS recommended to continue the study to modification.

We're very excited also to report that the top line data from another time compound of ANAVEX 3-71 is received often drug designation by the FDA for Frontotemporal dementia,, a placebo control Phase 1 study in ANAVEX 3-71 evaluating 371 in humans are expected around calendar 2021. During 2022, we were also moving closer to further expanding the pipeline for 273 using gene biomarkers of respond, applying precision medicine for another neurological disorder with unmet medical lead, including a plant initiation [ph] of 273 imaging focus, heart disease clinical study. A plant initiat initiation also of a Phase 2 cell three clinical trials for the treatment of a new rare disease indication and lastly, a planned initiation of a pivotal Phase 2 specialty of a new [indiscernible] the most genetic cause of [indiscernible].

In Federal [ph], most frequent announced August of this year data [indiscernible]. I would like to direct the call to Sandra Boenisch, Principal Financial Officer for a brief financial summary of the recently reported year end.

Sandra Boenisch

Thank you, Christopher and good afternoon to everybody. We continue to maintain a strong balance sheet and fiscal responsibility. Our cash position on September 30, 2021 was $152.1 million, which we believe is sufficient cash runway to fund operations and clinical programs beyond 2025. During fiscal 2021 cash utilization and operations was $30.4 million. We reported a net loss of $37.9 million for the full fiscal year, which is $0.54 per share as compared to $26.3 million or $0.45 per share in the comparable year 2020.

Research and development expenses for the year were $33 million compared to $25.2 million for the comparable fiscal year. The increase is primarily attributable to the continued advancement of our ongoing clinical trials. Most notably the full enrollment of our international Phase 2B/3 Alzheimer's disease trial and the related open label extension and the continued enrollment and advancement of the Rett Syndrome studies and expansion of these trials internationally. General and administrative expenses were $9 million for the year as compared to $5.9 million in the prior year. The increase is mostly significantly associated with an increase in personnel and associated non-cash stock option compensation charges.

Thank you. And now I'll return the call back over to you, Christopher.

Christopher Missling

Thank you, Samra. And as we look to the remainder of 2021 and into 2022, I'm very excited about the company's potential as we continue to advance and expand our position medicine to programs. As we look ahead, we will continue to focus on driving meaningful growth across our broad CMA one platform, portfolio to deliver transformational treatments for patients with both degenerative and developmental neurological disorders around the world.

So we look forward to providing further updates of advanced and continue and at this point, I like to also wish everyone a happy Thanksgiving. I would like now to open the call for questions. Operator, please go ahead.

Question-and-Answer Session

Operator

[Operator instructions] And our first question comes from Charles Duncan from Cantor Fitzgerald. Your line is open.

UnidentifiedAnalyst

This is Pete [ph] for Charles. Good afternoon Christopher and team and congratulations on the progress and appreciate all the updates. I have a couple of questions regarding Rett Syndrome. When you think about the efficacy measures that were made in the efficacy scene in the US adult study, how do you feel about the samples size or the planned effect size out of AVATAR and also the excellence study. And we saw that you upsized the sample size for excellence from 69 to 84 subjects which role that decision, if you can give us some color on that.

Christopher Missling

Appreciate it and thank you. So the efficacy effect size was really significant in the first US study, which was using a low dose, as you remember, and the effect size was in the range 1.3 to 1.1 -- 0.3, which is considered very large. And since we expect those response based on higher doses, we basically inclined to believe that the second study, the other AVATAR study might show a similar if not higher effect size, given that we are using a higher dose in the AVATAR study compared to the US study.

The extension of patient number in the excellent study from originally 69 to 84 was based on a request a regulatory request to also have an additional sub analysis of the number of patient in different age groups for example, from five to 18 to also have an additional analysis of patients from five to 12, and then from 12 or 13 to 18 in order to make sure we have enough power for this additional calculation, we thought it was prudent to just add additional number of patients with ended up to the total number of 84 as we communicated.

UnidentifiedAnalyst

Thank you. Very helpful. We also saw that you made a few changes to the primary and second very endpoint in the excellent study. Can you give us a help us understand on what drove those decisions, was a result of advice or interactions with the FDA or any other regulatory agency,

Christopher Missling

Right. So we have noticed that the RSQ is really the most rigorous, more rigorous endpoint. It is really going through 45, very dedicated questions and detailed question, which can be answered very precisely. There's also the ability which we have seen, and we have demonstrated that in our presentation of doing sub-analysis of the sub scores of the entire score of the RSPQ, however, when we look at that we noticed that there was a weaker ability to make this because it's a really a global assessment and it also has a very known and it's published weak I would say reliability, but we basically include that still, but we didn't want to overemphasize that score. So that was the background for the focus on the RSPQ.

UnidentifiedAnalyst

All right. Thank you. And my last question regards to the Parkinson's disease dementia program, can you provide any updates on that program, have you met with the agency to discuss it and or do you plan to anytime in the near future?

Christopher Missling

Yeah, we plan, Right. Thank you very much. Yes. We plan to do that. We actually are in the process of now discussing the data with the foundations and we are expecting to get a valuable feedback for input on the design of pivotal studies for Parkinson and also pivotal study for Parkinson dementia. And with that, in our package, if you like, we then feel more robustly educated and fully informed to go to do the discussion with the agency about a proper pivotal study in the respective communications.


UnidentifiedAnalyst

Do you think, by some chance you're going to wait for the imaging study results or it'll the meeting will occur beforehand.

Christopher Missling

This will be before the imaging study, but definitely we are still including which we have not yet reported the total gene analysis of the PD study. So that means we've not only looked at the Sigma one gene expression changes of the mRNA, but also the gene expression of all participants that is in the active arm, as well as in the placebo arm and believe that additional intelligence can be drawn out that to make an informed design of a study, which increases further the chances of a pivotal study down the road.

UnidentifiedAnalyst

All right. Thank you. Thank you very much for taking my questions and congratulations again on the progress and happy Thanksgiving,

Christopher Missling

Thank you.

Operator

Next question comes from Raghuram Selvaraju from H.C. Wainwright. Your line is open.

Raghuram Selvaraju

Congrats for the progress and thanks for taking our questions. So firstly, how early in 2022, do you envisage filing an NDA for [indiscernible] in Rett Syndrome, providing you positive readouts from the three trials?

Christopher Missling

It's really, I would let the data first come out and then we can talk about that, but obviously pending data as soon as possible.

Raghuram Selvaraju

Excellent and then with regards to 2-73 what learnings are you transitioning into your Fragile X syndrome development? For example, are you planning on cross analyzing data from the Rett Syndrome and the fragile X syndrome trials, given that the two syndromes sort of share over overlapping symptoms as well as underlying cellular mechanisms?

Christopher Missling

That exactly right. So two pockets here to look at one is the preclinical pocket, and we see a very strong in the animal model of a Fragile X and leading to even reversal of the pathology. And then we look also at the clinical study of the Rett Syndrome, and we see that the phenotypes are overlapping between these two indications. And there are some end points, which are included in the Rett Syndrome study for example, atoms [ph] is one of them and that had been responding very well with the drug and we believe this could be also used as a key measure for the Rett Syndrome for the Fragile X study, since that has been also even used prior in Fragile X study as our primary endpoint. The decision is not yet made exactly about how to use that endpoint, but this could be one potential venue.

Raghuram Selvaraju

Okay. Very helpful. And we read with interest your recent published paper in expert opinion on therapeutic targets where you described 273 and 371 as hand in hand targets for Alzheimer's disease. We were wondering if you've number one, benchmark these drugs together pre-clinically, and number two, test a company nation if not, do you plan to do so.

Christopher Missling

So the two compounds came from different angles and different labs but they are now moving more into what we call, we try to learn as we go. But so far we could not find parable assay other than a very early preclinical assay of target engagement. And there are differences in the affinities of the Sigma 1 receptor and also difference to the muscarinic receptor, which we believe is also important.

And ultimately we will be only able to see really the difference of the two if we run really both indication world drug and the same indication in the same trial. So we think that each drug has its own merits and it could very well be that 371 is really good at focusing more in Frontotemporal, and could also be very good at [indiscernible] but right now we have 273 more advance, so we will eventually find out,

Raghuram Selvaraju

Appreciate the color. And then just finally you've talked about 273 using in a prophylactic manner. We saw a recent science advances article, which describes a unique kind of brain protein signature in younger cohorts, mean age of 39. Are you currently working on or planning a genetic or protein test in a younger cohort to kind of help your 273 administration in the future?

Christopher Missling

Yeah, we look into that and it's a very good point because while the disease is showing up correlating with age, it's clear that early intervention is really most likely the most efficient way to incubate this disease. And our preclinical data indicates that potential, which was done very successfully in animals that who got the drug before they got injected with a toxic, a better load. And they never developed the symptoms of Alzheimer disease. So there's really high likelihood that we should or encouragement to also proceed. And we sat and we committed to eventually do that with the appropriate in the appropriate time, down the road. So we are committed to look into that what you described early on.

Raghuram Selvaraju

Okay. Excellent. That's it from us? Congrats again, and happy Thanksgiving to you and everyone on the call. Thanks.

Operator

Next question comes from Soumit Roy from Jones Trading. Your line is open.

Soumit Roy

Hello everyone. And thank you for taking the question. Could you give us a little color around the upcoming Rett study? So as I understand, there will be different dose cohorts. So is, could you give us an idea of the size and is there going to be intra cohort dose escalation? What should we expect?

Christopher Missling

Yeah. So let me explain that there is not a different dose. It's just a target dose is higher than the US study. So there's only one dose and one placebo arm, and that one dose will be a target dose. So that is just higher than the US study. So there will be not multiple doses, technically it's just one higher dose.

Soumit Roy

Okay. Got it. So, and you are not disclosing if it's going to be 10, 20 or 30,

Christopher Missling

Right. We will find out when we disclose the data and then we'll be able to learn about that.

Soumit Roy

Got it. And any color on the Alzheimer's trial, what are you planning as patients are coming out of the 48 week? Is, are they going to go into maintenance trial or what is the plan there?

Christopher Missling

Right. So we have an extension study called Attention ID, which is a two year study of following up as an open label after the 48 week, which has started, after the first patient finished the 48 weeks. And because these patients have actually, some of them finished this phase two open label extension, they had requested to continue to stay on the study drug.

And so what we did, we initiated and we're successful in expanding now this attention AB study open label extension from two years to three years. So patients who are finish the study, the placebo control study, enter into the extension study finish the two years will now continue to go into the third year. And that is because of request by the patient, the caretakers and the physician. It also, I like to add that the I like to add also that the conversion from the placebo controlled part of the study to the open label is very high it's above 94% currently, which is a good sign.

Soumit Roy

Great. It's really good to hear. And one last question on the back to the Rec program, where are you on the conversation turning whether these going to be the data [ph]

Christopher Missling

It's really a question now of the data and the data has to speak for itself. And we also said it's a potential pill study. So the word really weighs in, and the data really will determine this how this will be looked at. We have to point out that for adults, there is no treatment available. And the patient population is also harder to bring into the trial because they're more at large. They also are because of the disease early passing on, they're not many patient available to find in a trial. So the focus is really on the study for that reason, but still there's an unmet need for patients of all ages for X syndrome.

So we could expect, you could even start a rolling submission with the adult trial, if need be that could be approved first before the pediatric really gets filed. I would say it cannot be excluded and, but I cannot promise it either. So that's why I said we would have with ANAVEX [ph] study and the US two independent placebo control study in disease, which usually is beyond the request from for rare diseases usually. So this will be successful, a very powerful package.

Soumit Roy

Got it. Congratulate again for on all the progress and happy Thanksgiving.

Christopher Missling

Happy Thanksgiving. Thank you,

Operator

Next question comes from [ph] from BTIG. Your line is open.

Unidentified Analyst

Hi. Thanks very much for taking the question. So the first one is on Rett Syndrome and so the definition of a responder, is that on each efficacy endpoint, is that going to be the same in pediatric patient as two, an adult patient, and also the definition of a responder is that consistent with how clinicians are viewing as clinic meaningful improvement?

Christopher Missling

That's correct. It's consistent first study and then consistent with the assessment. That's correct.

Unidentified Analyst

Okay. Then I think I didn't see an update on the 371 program in 2020 sorry, 2022 in terms of upcoming milestone. So I just wanted to check if frontal temporal dementia is still going to be the first indication for that program. And when do you expect a study potentially to start.

Christopher Missling

Right. So we have mentioned that we would move ahead with prototype dementia, but we like to have really the solid phase one data in hand before we say we commit to this. And but we definitely will move forward with FTD or any other related dementia indication.

Unidentified Analyst

Okay. And then on the pipeline, I think well, it's very encouraged to be able to target multiple indications, but just wonder which indications do you think you would like to prioritize going for? Of course, the Rett Syndrome and is going to be the lead indication, but which indication do you think might be suited for partnerships?

Christopher Missling

So we believe that we have with the red disease franchise, which is Rett Syndrome FX and others the ability, and it's not been the first time that a company has built this into a commercial entity with the disease targeting rare diseases. So that seems to be very doable. It comes to the indication like Alzheimer disease and Parkinson disease, which requires also the involvement of a detailing practitioners, physicians of general physicians. Then it might be more powerful to penetrate the market with the support of a large pharma partner and at the right time to make sure that we retain most upside for Anavex and for our holders, this will be done at the right time and not to prematurely to give up to much of the upside, but it is no doubt that these large indications require additional support.

Unidentified Analyst

Okay, great. Thank you very much. And happy Thanksgiving.

Operator

And your next question comes from [indiscernible]. Your line is likewise. And that concludes the question and answer portion. And it also concludes the conference call. Thank you for participating. You may now disconnect.



26/11 2021 06:57 Kyed01 898890



Anavex præsenterer på ALS konference 29-30 november.

Interessant nok er det Nell Rebowe som gør det, som jeg har checket lidt på.

Hun er meget smuk og er også foto model.

Hvis nu hun havde præsenteret tidligere i stedet for den tørre Missling ville kursen nok værre over 100 allerede, ha-ha.

https://2021alsoneresearchsymposium.splashthat.com/?fbclid=IwAR0gzPM7QjhtoMiBLKCSxOKdo9SQSxygLPjQwiqMjYmY-CKTTC1ZqfiJkTA


https://www.nextmanagement.com/miami/profile/nell-rebowe



26/11 2021 20:02 Budweis 598925






26/11 2021 20:42 Solsen 598926



Hvis ikke man kigger på Ihub så følger dette svar fra MayoMobile på spørgsmål om Cohens Effect size

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166914423

Interessant at der er supergode Cohens effect size i rett og alzheimers i sigma1 varianten wildtype.



29/11 2021 13:10 Tasso1 598991



Anavex Live Webcast torsdag den 2. december

https://newsfilter.io/a/12a6afff289272725b9d50855e3bbb2d

Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET. - 18.10 DK-tid.

https://www.anavex.com/investor-material

Nell Rebowe er jo også på i morgen tirsdag med ALS.


Der kan komme nyheder hver dag nu - spørgsmålet er om "around end of year" allerede er denne uge?
Bemærk at webcastet den 2. dec. er i åbningstiden - så der vil blive kontant markedsafregning ved gode/dårlige nyheder.




29/11 2021 15:59 Tasso1 599003



Anavex Evercore ISI HealthCONx Conference

Dette er en såkaldt "Firesite" konference, hvor man udover muligheden for at afholder et webcast, som Anavex, også kan mødes med andre biotekselskaber - alle de store BP er der også som regel.
Så måske Missling skal sidde lidt i en læderstol ved pejsen, med en god cognac i hånden og sludre lidt med potentiel kommende partner - efter han lige har præsenteret lidt gode data?

Hvem ved, men det er i hvert fald det konceptet går ud på!

Fik lige købt for 50.000 kr. til kurs 19.99 $ ved åbning - måske sidste gang aktiekursen var under 20 $??




TRÅDOVERSIGT